In CLL muated/unmutated is beginning to matter in treatment choice.. but what about the other large component ...sex??
Surely in the fledgling era of personalised medicine this should be looked at?
A recent study look at this in DLBCL, think Richter's, and the use of rituxan a component in RCHOP, indicates that a higher dose in men was of great benefit...
As the study states
We conclude that the higher rituximab dose for elderly male patients abrogated the adverse prognosis of male sex without increasing toxicity. In the era of personalized medicine, sex-specific pharmacokinetics and toxicities should be investigated for all drugs where these parameters impact on outcome.
Food for thought... is there a similar poorer male prognosis in CLL?